Eversept Partners’s Novavax NVAX Stock Holding History

Eversept Partners’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-181,220	Closed	-$1.22M	–	142
2025 Q4	$1.22M	Sell	181,220 -61,964	-25%	-$467K	0.06%	97
2025 Q3	$2.11M	Buy	+243,184	New	+$1.89M	0.15%	68
2025 Q2	–	Sell	-365,523	Closed	-$2.34M	–	71
2025 Q1	$2.34M	Buy	+365,523	New	+$3.02M	0.24%	40
2021 Q2	–	Sell	-33,473	Closed	-$6.13M	–	102
2021 Q1	$6.07M	Buy	+33,473	New	+$6.67M	0.31%	46

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eversept Partners's NVAX Position: Q1 2026 in Review

Eversept Partners sold out of Novavax (NVAX) in Q1 2026, closing a stake of 181,220 shares — an estimated $1.22M sold.

Eversept Partners first reported a position in NVAX in Q1 2021 and held it in 4 quarters. The position peaked at $6.07M in Q1 2021. 259 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

Eversept Partners reported no remaining Novavax position as of Q1 2026 after selling out during the quarter.
Eversept Partners sold 181,220 Novavax shares in Q1 2026, an estimated $1.22M.
Eversept Partners first reported a position in Novavax in Q1 2021 and held it in 4 quarters.
Eversept Partners's Novavax position peaked at $6.07M in Q1 2021.
259 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.